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While the defects in HLA class I-mediated Ag presentation by Burkitt lymphoma (BL) have been well documented, CD4+ T-
cells are also poorly stimulated by HLA class II Ag presentation, and the reasons underlying this defect(s) have not yet been fully
resolved. Here, we show that BL cells are deﬁcient in their ability to optimally stimulate CD4+ T cells via the HLA class II pathway.
The observed defect was not associated with low levels of BL-expressed costimulatory molecules, as addition of external co-
stimulation failed to result in BL-mediated CD4+ T-cell activation. We further demonstrate that BL cells express the components
of the class II pathway, and the defect was not caused by faulty Ag/class II interaction, because antigenic peptides bound with
measurable aﬃnity to BL-associated class II molecules. Treatment of BL with broystatin-1, a potent modulator of protein kinase
C, led to signiﬁcant improvement of functional class II Ag presentation in BL. The restoration of immune recognition appeared
to be linked with an increased expression of a 17kDa peptidylprolyl-like protein. These results demonstrate the presence of a
speciﬁc defect in HLA class II-mediated Ag presentation in BL and reveal that treatment with bryostatin-1 could lead to enhanced
immunogenicity.
1.Introduction
Burkitt lymphoma (BL) is an aggressive non-Hodgkin’s B-
cell malignancy, occurring most frequently as endemic BL in
children living in areas of high malarial prevalence [1]. This
malignancy may also be found in other parts of the world
as sporadic BL and accounts for 1-2% of all lymphomas
in Western countries [1]. The clinical manifestations of
BL are variable, with tumors of the jaw characteristically
seen in endemic BL and tumors in the gut associated with
sporadic BL [2–4]. BL has one of the fastest doubling times
among human malignancies and is frequently associated
with immune deﬁciency [3].
In addition to its strong association with malaria, BL
has a high correlation with Epstein-Barr Virus (EBV). EBV
infection, however, is not requisite for the development of
BL, and the degree of association with EBV varies based on
the type of BL. EBV infection occurs in >90% of endemic
BL cases, 10–15% of sporadic BL, and 40% of human
immunodeﬁciency virus (HIV) associated BL [1]. While
the exact role that EBV plays in the development of BL
remains largely unknown, it is understood that EBV gene
products may be involved in the transformation of BL cells
and their decreased immunogenicity. Additional evidence
for EBV having a role in development of BL stems from
EBV’slinktovariousotherlymphoidmalignanciesincluding2 Clinical and Developmental Immunology
Hodgkin’s lymphoma, transplant-related B-cell lymphomas,
T-cell lymphomas, adult T-cell leukemia, and natural killer
cell leukemia [5–8]. While BL has varying associations with
malaria and EBV and in some cases is not associated with
either, the one feature shared by all BLs is overexpression
of the oncogenic transcription factor c-myc, which has a
gene network comprising up to 15% of all known genes [9].
This abnormality results from the translocation of the MYC
gene to an immunoglobulin locus leading to its constitutive
activation [10–12].
BL is known to be deﬁcient in HLA class I-mediated
antigen (Ag) presentation to CD8+ T lymphocytes [13–15].
However, the role of HLA class II-mediated Ag presentation
in generating an immune response to BL has not been
fully elucidated. The class I defect has been well studied
and is understood to result from the weak immunogenicity
of EBV nuclear Ag 1 (EBNA1), which is poorly processed
and presented through the class I pathway [16–18]. Another
EBV gene product, gp42, has a role in mediating virus
binding through interaction with HLA class II and it has
been speculated to block the interaction between class II and
the T-cell receptor [19, 20]. Although HLA class I-mediated
activation of CD8+ T cells leads to Ag-speciﬁc lysis of tumor
cells, an HLA class II response is vital for the generation
of sustained immune responses [21]. Our laboratory has
previously shown that B-cell lymphomas are deﬁcient in
HLA class II-mediated Ag presentation [22], and in this
study we explore the role of B-cell-associated molecules in
restoration of CD4+ T-cell recognition of BL cells.
The study presented here suggests that multiple defects
may contribute to BL’s inability to eﬃciently present Ag
via HLA class II molecules. We conﬁrm expression of
a transfected HLA class II allele in both BL cells and
EBV-immortalized B-lymphoblastoid cells (B-LCL), and
demonstrate that the transfected HLA class II eﬃciently
binds exogenously delivered Ag to form class II peptide
complexes. However, while B-LCL were capable of CD4+ T-
cell stimulation, BL cells were deﬁcient in their ability to do
so, and addition of external co-stimulation was insuﬃcient
to overcome this defect. In addition, treatment of BL cells
with bryostatin-1 partially restored class II-mediated Ag
presentation. This restoration was linked to the upregulation
of a 17kDa protein in bryostatin-treated BL which was
expressed at low levels in untreated BL but highly expressed
in B-LCL, suggesting that this protein may play a role
in enhancing class II-mediated Ag presentation. In other
studies, bryostatin-1 has been shown to increase HLA class
II expression in dendritic cells and in a colorectal carcinoma
cell line, but its eﬀe c to nH L Ac l a s sI Ie x p r e s s i o na n dA g
presentation in lymphoid malignancies has not previously
been evaluated [23, 24]. On the whole, these results suggest
that BL possesses multiple defects which lead to an impaired
ability to stimulate CD4+ T cells through HLA class II Ag
presentation. These defects may provide the opportunity to
develop novel immunotherapies leading to more targeted
treatment of BL and other lymphoid malignancies. This
study also provides a rationale for the further evaluation
of bryostatin-1 as a therapeutic treatment of lymphoid
malignancies.
2.MaterialsandMethods
2.1. Cell Lines. Human BL cell lines, Nalm-6, Ramos, and
Ous, were maintained in complete RPMI-1640 supple-
mented with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA), 50U/mL penicillin 50μg/mL streptomycin, and 1% L-
glutamine (Mediatech, Manassas, VA). The Ous cell line was
a gift from Dr. Christian Munz (Rockefeller University). The
human B-lymphoblastoid cell lines (B-LCL) 6.16 and Frev
were maintained in IMDM supplemented with 10% bovine
growth serum (Hyclone, Logan, UT), 50U/mL penicillin
50μg/mL streptomycin, and 1% L-glutamine (Mediatech).
Nalm-6, Ramos, and 6.16 cells were retrovirally transfected
for constitutive expression of HLA-DR4 (DRB1∗0401) with
linked drug selection markers for hygromycin and histidi-
nol resistance to generate Nalm-6.DR4, Ramos.DR4, and
6.16.DR4 [22, 25]. Frev did not require transfection of the
class II allele as it constitutively expresses HLA-DR4. Surface
HLA-DR4 expression in the transfectants was conﬁrmed by
ﬂow cytometric analysis using the DR4-speciﬁc mAb, 359-
F10 [22, 26, 27]. 6.16.DR4 cells were further transfected
with DMα and DMβ for constitutive expression of HLA-DM
molecules to generate 6.16.DR4.DM [22]. The expression of
HLA-DM on 6.16.DR4.DM cells was conﬁrmed by western
blotting. T-cell hybridomas 2.18a and 1.21 recognize Ig
κ residues 188–203 and 145–159, respectively, and were
generated by immunization of DR4-transgenic mice as
described [25, 28]. The T-cell hybridoma 17.9 (generously
provided by D. Zaller, Merck Research Laboratories, Rahway,
NJ) responds to human serum albumin (HSA) residue 64–
76K[29].TheseTcellhybridomasarelessdependentoncos-
timulatory signals for their stimulation. Cells were cultured
in RPMI 1640 with 10% FBS, 50U/mL penicillin, 50μg/mL
streptomycin, and 50μM β-mercaptoethanol (Invitrogen).
2.2. Antigens, Peptides, and Other Reagents. Human
serum albumin (HSA) and human IgG kappa (IgG κ)
were purchased from Sigma (St. Louis, MO). HSA64–76K
peptide (sequence: VKLVNEVTEFAKTK) human IgG
immunodominant peptide κ188–203 (κI; sequence:
KHKVYACEVTHQGLSS), and subdominant peptide
κ145–159 (κII; sequence: KVQWKVDNALQSGNS) were
producedusingFmoctechnologyandanAppliedBiosystems
Synthesizer as described, dissolved in PBS, and stored at
−20◦C until used [25, 29, 30]. Reverse phase HPLC
puriﬁcation and mass spectrometry were used to analyze the
peptide and showed a peptide purity >99%. Bryostatin-1
was purchased from Sigma.
2.3. Antigen Presentation Assays. B-LCL and BL were incu-
bated with 0μM, 5μM, 10μM, or 20μM HSA Ag or HSA
synthetic peptide for 3–24h at 37◦C in the appropriate cell
culture media to determine optimal antigen concentrations
to use in antigen presentation assays [22, 25]. Following
titration, the same assays were carried out using only the
optimal concentration of each antigen. Cells were then
washed and co-cultured with the T-cell hybridoma 17.9
for 24h at 37◦C. In parallel assays, 2.18a and 1.21 wereClinical and Developmental Immunology 3
stimulated with anti-CD3/CD28 prior to co-culture with
Nalm-6.DR4, Ramos.DR4, or 6.16.DR4.DM which had been
incubated with κIo rκII [29]. Following co-culture, T cell
production of IL-2 was quantitated by ELISA [31]. Assays
were repeated in triplicate with standard error for triplicate
samples within a single experiment being reported.
2.4. Western Blotting. Western blot analysis was performed
on whole cell lysates of Frev, Nalm-6.DR4, 6.16.DR4.DM,
and Ramos.DR4. Expression of HLA class II, Ii, and HLA-
DM was analyzed as described previously [32, 33]. Den-
sitometry was performed using a ChemiDoc XRS station
(Bio-Rad) where the protein bands were analyzed using
the Quantity One 4.6.3 software (Bio-Rad). Relative protein
expression levels were stated as a ratio of speciﬁc proteins
expressed/β-actin for each sample. Data are representative of
at least three separate experiments.
2.5. IL-2 ELISA. IL-2 levels in Ag presentation assay super-
natant were quantitated by ELISA. A 96-well ELISA plate was
coated overnight at 4◦C with puriﬁed rat anti-mouse IL-2
(Sigma). The plate was then washed and blocked with 2%
BSA at RT for 30m. After washing, standards and samples
were plated in appropriate wells and incubated at RT for
2h. A standard curve was generated using recombinant IL-
2 purchased from R&D (Minneapolis, MN). The plate was
washed, and biotinylated rat anti-mouse IL-2 (Sigma) was
addedandincubatedatRTfor1h.Followingwashing,avidin
peroxidase (Pierce, Rockford, IL) was added to each well and
incubated at RT for 30m. The plate was washed, and PNPP
substrate (Thermo Scientiﬁc, Rockford, IL) was added to
each well and incubated at RT. Readings were taken every
30m at 405nm. IL-2 levels in sample wells are expressed
in pg/mL, calculated from the standard curve. Assays were
repeated in triplicate and expressed as mean IL-2 ± SEM.
2.6. Peptide Binding Assays. Nalm-6.DR4, Ramos.DR4,
6.16.DR4.DM,and Frevcellswere ﬁxed in 1% paraformalde-
hyde and then incubated overnight with 0μM, 10μM, or
20μM biotinylated HSA peptide (b-HSA) in 150mM CPB
(pH 7.4), washed with PBS, and lysed on ice for 20min
with 50mM Tris buﬀer (pH 8) containing 0.15M NaCl and
0.5% IGEPAL CA 630 (Sigma) as described [30, 34]. Cell
supernatants were added to plates (Costar, Cambridge, MA)
previously coated overnight with the anti-human class II
antibody37.1(kindlyprovidedbyL.Wicker,MerckResearch
Lab, Rahway, NJ). The captured class II-peptide complexes
were detected with europium-labeled streptavidin (Pharma-
cia Fine Chemicals, Piscataway, NJ) using a ﬂuorescence
plate reader (Delﬁa, Wallac, Turku, Finland). The number of
total DR molecules within B-LCL/BL cells was quantitated as
described [28].
2.7. Bryostatin-1 Treatment of BL Cells. Nalm-6.DR4 and
Ramos.DR4 were treated with 0, 20, or 40nM of bryostatin-
1 for overnight. Following incubation, untreated and
bryostatin-treated cells were used in Ag presentation assays
with HSA peptide followed by ELISA IL-2 quantitation
as already described. In separate assays, Ramos.DR4 were
treated with 40nM bryostatin overnight and then ﬁxed in
1% paraformaldehyde for 5min. Following ﬁxation, the cells
werewashedandincubatedwith0μM,10μM,or40μMofb-
HSAfor3hat37◦Cwithshaking.Thecellswerethenwashed
andlysedinHanksBalancedSaltSolutionwith1%Triton-X-
100 and protease inhibitors (PMSF and TLCK). The lysate
was added to wells of a 96-well plate precoated with the
anti-HLA class II antibody, 37.1. Captured class II peptide
complexes were detected using streptavidin peroxidase and
BD OptEIA TMB substrate reagents (BD, San Diego, CA).
The reaction was stopped using 1M phosphoric acid and the
resulting absorbance was read at 450nM.
Additionally, surface protein expression in 6.16.DR4.
DM, untreated Nalm-6.DR4, and bryostatin-treated Nalm-
6.DR4 was evaluated by SDS-PAGE protein separation.
Nalm-6.DR4 cells were treated overnight with 40nM
of bryostatin-1. Following incubation, 6.16.DR4.DM,
untreated Nalm-6.DR4, and bryostatin-treated Nalm-6.DR4
were washed in citrate phosphate buﬀer (CPB) to elute cell
surface proteins. The resulting eluate was then subjected
to SDS-PAGE. A 17kDa band was excised from these gels
a n da n a l y z e db yM A L D IT O F - T O Fm a s ss p e c t r o m e t r y .
Proteins in CPB eluate from 6.16.DR4.DM were separated by
electrophoresis on large, nonreducing gels. The 17kDa band
was excised and the protein was extracted by sonication in
PBS on ice. Ramos.DR4 cells were incubated with the HSA
peptide in the 17kDa extract for use in Ag presentation
assays as described. T cell production of IL-2 was quantitated
[31].
2.8. Protein Extraction and Digestion. CPB eluate was
obtained from 6.16.DR4.DM, untreated Nalm-6.DR4, and
bryostatin-treated Nalm-6.DR4 as described previously [22].
Extracts were concentrated, and protein concentrations were
measured, then run on a non-reducing gel, and stained
with Coomassie blue. Gel plugs were excised and placed
in an eppendorf tube. Each plug was washed with 50mM
ammonium bicarbonate for 10 minutes. Next, the plugs
were destained using 25mM ammonium bicarbonate in
50% acetonitrile for 15 minutes. The plugs were dehydrated
with 100% acetonitrile for 15 minutes and dried in a
speedvac. Each gel plug was covered with Proteomics Grade
Trypsin (Sigma) and incubated at 37◦C overnight. The
supernatant was collected in a clean dry eppendorf tube.
Peptides were further extracted with 1 wash of 25mM
ammonium bicarbonate for 20 minutes and three washes of
5% formic acid, 50% acetonitrile for 20 minutes each. The
supernatent was collected and pooled after each wash then
dried down in a speedvac to ∼1uL. Prior to analysis, the
sampleswerereconstitutedwith10uLof0.1%triﬂuoroacetic
acid. Samples were then concentrated with a C18 Ziptip
(Millipore) and eluted with 0.1% TFA, 50% acetonitrile, and
7.0mg/mL α-cyano-4-hydroxycinnamic acid directly onto
the MALDI target.
2.9. Mass Spectrometric Analysis (MALDI TOF/TOF). After
the spots were dried completely, the plate was loaded into the4 Clinical and Developmental Immunology
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Figure 1: BLs are deﬁcient in their ability to present Ag in the context of HLA class II. BL (Nalm-6.DR4, Ramos.DR4, and OUS) and B-LCL
(6.16.DR4.DM and Frev) were incubated with whole HSA (a and c) or HSA synthetic peptide (b and d). Following incubation, cells were
washed and co-cultured with the HSA64–76k epitope-speciﬁc T-cell hybridoma 17.9. Supernatant from the co-culture was assayed by ELISA
to determine IL-2 levels as a measure of T-cell stimulation. All three BL cell lines were deﬁcient in stimulation of IL-2 production for both
whole HSA and HSA synthetic peptide, while both B-LCL eﬃciently presented each Ag to stimulate high levels of IL-2 production.
Applied Biosystems 4800 Proteomics Analyzer. An external
calibration was performed prior to analyzing samples uti-
lizing the manufacturer’s standards and protocols. Samples
were analyzed in batch mode using 2000 laser shots per
spectrum. First, peptide mass maps were acquired over the
m/z range of 800–3500 in reﬂectron mode with a delayed
extraction time optimized for m/z 2000 by averaging 2000
scans to locate peaks of peptide origin. The next batch
r u np e r f o r m e dM S - M Sa n a l y s e st oo b t a i ns e q u e n c ed a t a
on the 20 most abundant peaks from the MS analysis.
Upon completion of the batch processing, the data was
exported into the GPS Explorer data processing system for
interpretation and identiﬁcation. The MASCOT database-
searching algorithm analyzed the data and summarized the
results in report format. Database searches were performed
using 2 missed cleavages and one diﬀerential modiﬁcation
of methionine oxidation. The top 20 matches were reviewed
prior to assigning conﬁdent protein identiﬁcations.
3. Results
3.1. BL Cells Display Decreased HLA Class II-Mediated CD4+
T-Cell Stimulation. Although BL and B-LCL both express
surface HLA class II, we transfected these cell lines to express
acommonclassIIallelesothatwemightobtainamoredirect
comparisonofclassII-mediatedAgpresentationbetweenthe
two cell types. Retroviral gene transfections of a DR4 allele,
HLA DRB1∗0401, were carried out on our BL (Nalm-6 and
Ramos) and B-LCL (6.16) cell lines. Flow cytometric analysis
conﬁrmed transfection and expression of this allele in all
three cell lines (data not shown). 6.16.DR4 cells were addi-
tionallytransfectedwithHLA-DMtogenerate6.16.DR4.DM
cells expressing similar levels of HLA-DM when compared to
Nalm-6.DR4 and Ramos.DR4 [33]. Transfectants were then
sorted, matched for surface DR4 expression, and incubated,
along with Ous and Frev, in culture media with either HSA
antigen or HSA peptide. Following incubation, cells wereClinical and Developmental Immunology 5
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Figure 2: BL and B-LCL express similar levels of HLA class II pathway components. Variations in eﬃciency of Ag presentation between BL
and B-LCL may be attributable to diﬀerences in expression levels of components in the class II pathway. To evaluate this possibility, the BL
cell lines Nalm-6.DR4 and Ramos.DR4, the B-LCL cell lines 6.16.DR4.DM and Frev were analyzed by western blotting for expression of HLA
class II, invariant chain (Ii), and HLA-DM (a). Densitometric analysis conﬁrmed the expression of comparable levels of each of these class II
pathway components (b).
washed and co-cultured with the T-cell hybridoma, 17.9,
for 24h at 37◦C. Culture supernatant was collected and
assayed by ELISA for IL-2 levels. The results of these assays
demonstrate that Nalm-6.DR4, Ramos.DR4, and Ous were
deﬁcient in their ability to stimulate IL-2 production in
17.9 by class II-mediated presentation of HSA epitope or
HSA synthetic peptide (Figures 1(a)–1(d)). The B-LCL lines
6.16.DR4.DM and Frev, however, stimulated production
of high levels of IL-2 (Figures 1(a)–1(d)). Supplemental
Figure 1 (see Supplemental material available online at
doi:10.1155/2011/585893) shows the results of whole HSA
and HSA peptide titration with Nalm-6.DR4, Ramos.DR4
and 6.16.DR4.DM. Nalm-6.DR4 and Ramos.DR4 fail to
stimulate IL-2 production at all concentrations of whole
HSA or HSA peptide, while 6.16.DR4.DM shows a dose-
dependentincreaseinlevelsofIL-2production.Theseresults
suggest that BL cells possess a defect(s) in the presentation of
Ag to CD4+ T cells in the context of HLA class II.
3.2. BL and B-LCL Express Similar Levels of HLA Class II
Pathway Components. Western blot analysis was performed
on Nalm-6.DR4, Ramos.DR4, 6.16.DR4.DM, and Frev for
expression of HLA class II, Ii, and HLA-DM. Data from
these analyses revealed that both BL and B-LCL expressed
detectable levels of these immune components (Figure 2(a)).
As a wild type B-LCL, Frev expresses higher levels of class
II pathway components than Nalm-6.DR4, Ramos.DR4, and
6.16.DR4.DM,asanalyzedbydensitometryandcorrectedfor
actin loading controls (Figure 2(b)). These data suggest that
the observed defect in class II-mediated Ag presentation by
BL is not the result of a defect in the HLA class II processing
and presentation pathway.
3.3. Addition of External Co-Stimulation Is Insuﬃcient to
Overcome the BL-Associated Defect in Class II-Mediated Ag
Presentation. It has previously been reported that BL cells
are deﬁcient in expression of co-stimulatory molecules
(CD80/86). In order to determine if this was the cause
of the defect in class II-mediated Ag presentation by BL,
Ag presentation assays were performed in the presence of
external co-stimulatory signals as described. In this assay,
T-cell hybridomas were treated with anti-CD3/CD28 plus
cross-linked IgG and co-cultured with the BL cells that
were preincubated with HSA peptide. The addition of
external co-stimulation had little to no eﬀect on class II
Ag presentation by BL (Figure 3). While 6.16.DR4.DM
stimulated high levels of IL-2 production in T cells
with or without external co-stimulation, Nalm-6.DR4 and
Ramos.DR4 showed no signiﬁcant increase in stimulation
of IL-2 production in T cells with external co-stimulation.
3.4. HSA Peptide Binds with Similar Aﬃnity to HLA Class II
on BL and B-LCL. The next step in evaluating the BL-related
defect in HLA class II Ag presentation was to assess the
binding eﬃciency of HSA peptide to BL-expressed surface
DR4. Nalm-6.DR4, Ramos.DR4, 6.16.DR4.DM, and Frev
were incubated with various concentrations of b-HSA at
pH 7.4. Class II peptide complexes were then detected
in an ELISA format using europium-labeled streptavidin.
Data showed a dose-dependent response with each cell line
binding b-HSA peptide with a similar, measurable aﬃnity
(Figure 4). These results suggest that BL’s reduced capacity to
present Ag via HLA class II is not a result of impaired peptide
binding to HLA class II molecules.6 Clinical and Developmental Immunology
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Figure 3: Addition of external co-stimulation is not suﬃcient to
overcomeclassII-associateddefectsinBL.BLsareknowntoexpress
lower levels of costimulatory molecules, raising the possibility that
thiswasthecauseoftheobserveddefectintheirabilitytopresentAg
via class II. BL cell lines Nalm-6.DR4 and Ramos.DR4, and the B-
LCL cell line 6.16.DR4.DM were incubated with κIa n dκII peptides
prior to co-culture with the T-cell hybridomas 2.18a or 1.21 which
hadbeenstimulatedwithanti-CD3/CD28.Culturesupernatantwas
assayed by ELISA for IL-2 levels as a measure of T-cell stimulation.
These results demonstrate that Nalm-6.DR4 and Ramos.DR4 Ag
presentationisunaﬀectedbytheadditionofexternalco-stimulation
and remains deﬁcient in class II-mediated presentation.
3.5. Bryostatin Treatment of BL Increases Peptide Binding
to HLA Class II and Restores Class II Ag Presentation and
CD4+ T-Cell Recognition. Previous studies on bryostatin-
1 have shown that it causes upregulation of HLA class II
molecules in the professional Ag presenting dendritic cells
and leads to increased T-cell stimulation by these cells [23].
Based on this ﬁnding, we sought to determine if bryostatin-
1 treatment would impact Ag presentation by BL. Nalm-
6.DR4 and Ramos.DR4 cells were treated with bryostatin-1
overnight and then used in Ag presentation assays with HSA
as already described. Untreated BL cells showed similarly
low levels of T-cell stimulation, whereas cells treated with
bryostatin-1 at 20–40nM restored Ag presentation and T-
cell stimulation (Figure 5(a)). Ramos.DR4 cells were treated
with bryostatin-1 overnight, and peptide binding to HLA
class II was measured as already described. Ramos.DR4
treated with 40nM bryostatin-1 showed signiﬁcantly higher
levels of peptide binding at both 10μMa n d4 0μM b-HSA
(Figure 5(b)).
3.6. Bryostatin Treatment Upregulates Expression of an
Immunostimulatory 17kDa Protein in BL. To determine the
nature of the class II presentation restoration in BL following
bryostatin-1 treatment, protein expression patterns in CPB
eluates from Nalm-6.DR4 and 6.16.DR4.DM were analyzed
by gel electrophoresis (non-reducing gel) and coomassie
blue staining. This study showed that a 17kDa protein was
consistently expressed at low levels in BL cells (Nalm-6.DR4)
but high levels in B-LCL (6.16.DR4.DM) cells (Figure 6(a)).
Following overnight treatment of BL cells with bryostatin-
1, expression of this 17kDa protein was restored to levels
comparable to 6.16.DR4.DM cells (Figure 6(a)). This protein
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Figure 4: BL and B-LCL bind HSA64–76K synthetic peptide with
similar aﬃnity. Ag presentation depends on eﬃcient binding of Ag
to HLA class II proteins. BL cell lines Nalm-6.DR4 and Ramos.DR4,
and the B-LCL lines 6.16.DR4.DM and Frev were ﬁxed and
incubated with biotin-labeled HSA64–76K at pH 7.4. Cells were lysed
and class II peptide complexes were detected in ELISA format with
europium-labeled streptavidin with mean ﬂuorescence used as a
measure of peptide binding. Each cell line bound similar levels of
peptide.
band was then cut from the gel and analyzed by MALDI
TOF/TOF mass spectrometry, revealing a peptidylprolyl-like
protein (accession number: 89058151). To further analyze
the function of this 17kDa protein, CPB eluates from
6.16.DR4.DM cells or bryostatin-1-treated BL cells were sep-
arated on a large non-reducing gel, the band corresponding
to 17kDa protein was excised, and the protein was extracted
by sonication in PBS on ice. Ramos.DR4 cells were then
incubated with HSA peptide (10μM) in the presence of this
extract, followed by washing and co-culture with 17.9 T cells.
ELISA IL-2 quantitation of the assay supernatant showed
a signiﬁcant increase in the stimulation of IL-2 production
by Ramos.DR4 cells incubated with HSA in the presence of
the 17kDa extract (Figure 6(b)). These results suggest that
bryostatin-1 treatment upregulates expression of a 17kDa
protein in BL, and this protein has an immunostimulatory
function.
4. Discussion
BLpossessesawell-knowndefectinHLAclassI-mediatedAg
presentation, resulting from the poor immunogenicity of the
EBNA1 protein. EBNA1 possesses an internal Gly-Ala repeat
that impairs its proteasomal processing, leading to weak
stimulation of CD8+ T cells [35]. This defect, although well
studied, addresses only one aspect of the immune response
to BL. Less is known about the role of HLA class II-mediated
immune responses to this malignancy. Studies have generally
focused on CD8+ T-cell responses due to their ability toClinical and Developmental Immunology 7
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Figure 5: Bryostatin treatment increased class II peptide binding and restored class II Ag presentation in BL cell lines. (a) The BL cell lines
Nalm-6.DR4 and Ramos.DR4 were treated with 0, 20, or 40nM bryostatin-1 for 24h. Following treatment, cells were collected, washed, and
incubated with HSA64–76K synthetic peptide for 24h. Cells were then washed and co-cultured with the T-cell hybridoma 17.9. Supernatant
from the co-culture was assayed by ELISA to determine IL-2 levels as a measure of T-cell stimulation. Results from these assays show
that bryostatin-1 treatment signiﬁcantly restores Ag presentation in both Nalm-6.DR4 and Ramos.DR4 to levels comparable to B-LCL.
(b) Ramos.DR4 cells were treated with 40nM bryostatin overnight and then washed, ﬁxed, and incubated with 0μM, 10μM, or 40μM
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∗P<0.001.
directly kill target cells, but CD4+ T-cell responses mediated
by class II are needed for lasting immune responses and
memory [36, 37].
In this study, we have shown that although BLs express
measurable class II proteins on their cell surface, they were
unable to stimulate CD4+ T cells through presentation of
HSA peptide or epitope. We demonstrate further that when
incubated in buﬀer at pH 5.5, BL cells regain class II-
mediated Ag presentation capacity. Treatment of BL with
bryostatin-1 led to restoration of class II presentation and
CD4+ T-cell stimulation. This restoration was due, in
part, to the upregulation of a 17kDa, immunostimulatory,
peptidylprolyl-like protein which is normally expressed at
very low levels in BL, but highly expressed in B-LCL.
The eﬃciency of class II-mediated Ag presentation to
C D 4 +Tc e l l sm a yb ep a r t i a l l ya ﬀected by the expression
levels of components in the class II pathway: Ii (invariant
chain),HLA-DMandHLA-DO[26,33,38].However,wedid
notobserveanysigniﬁcantdiﬀerencesintheexpressionlevels
of these pathway components between two BL and two B-
LCL cell lines, ruling this out as contributing to the observed
defect in BL. CD4+ T cell activation is also dependent on
signals delivered by the co-stimulatory molecules, CD80/86,
expressed by B cells, yet BLs are known to express lower
levels of these molecules [39]. It is plausible that the BL-
associated class II defect was a result of insuﬃcient co-
stimulation. External co-stimulation may be provided to T
cells in the form of anti-CD28, which serves as a surrogate
for CD80/86. While our T-cell hybridomas do not require
co-stimulation, we still evaluated whether the decreased
expression of co-stimulatory molecules contributed to the
BL defect. However, even under these conditions, BL cells
were unable to stimulate activation of CD4+ T cells. We
gleaned further evidence that co-stimulation is not the cause
the BL-associated class II defect from assays demonstrating
that cross-linking IgM on BL cells failed to result in CD4+
T-cell stimulation (data not shown).
The presentation of Ag via HLA is central to the immune
system’s ability to detect pathogens and transformed cells
and mount immune responses to these cells. Eﬃcient Ag
presentation is dependent on eﬃcient binding of peptides to
HLA.Whileco-stimulationwasnotthecauseofBL’sinability
to present Ag through class II, the possibility existed that
BL-expressed class II was not able to bind Ag eﬃciently,
thus preventing T-cell stimulation. Binding assays, however,
demonstrated that BL and B-LCL both bound peptide with a
similar, measurable aﬃnity.
Bryostatin-1, a potent modulator of protein kinase C,
has previously been shown to stimulate upregulation of
HLA class II in colorectal cell lines and dendritic cells
and to enhance Ag presentation in dendritic cells [23, 24].
To date, however, its eﬀect on HLA class II expression8 Clinical and Developmental Immunology
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Results show that IL-2 stimulation is signiﬁcantly increased in Ramos.DR4 cells incubated with peptide in the presence of the 17kDa gel
extract. ∗indicates P<0.05.
and Ag presentation in lymphoid malignancies has not
been evaluated. Based on this information, we sought to
determine if treatment with bryostatin-1 was suﬃcient to
enable restoration of class II-mediated Ag presentation to
BL. We found that the BL cell lines Nalm-6.DR4 and
Ramos.DR4 did indeed regain HLA class II Ag presentation
capacity following treatment with bryostatin-1. Our assays
with Ramos.DR4 cells demonstrated that restoration of HLA
class II Ag presentation could partially be due to increased
peptide binding by HLA class II following treatment with
bryostatin-1. Additionally, protein expression analysis fol-
lowing bryostatin-1 treatment showed a marked increase
in a 17kDa peptidylprolyl-like protein in Nalm-6.DR4,
which was expressed at very low levels in untreated Nalm-
6.DR4 and expressed at high levels in 6.16.DR4.DM. This
protein, when extracted and used in Ag presentation assays,
enhancedclassII-mediatedAgpresentationin6.16.DR4.DM
cells. Thus, bryostatin-induced restoration of class II Ag
presentation in BL cells was mediated by an increased
expression of a peptidylprolyl-like protein.
BL is a rapidly growing malignancy and thus requires
aggressive chemotherapy to control its spread. Currently
used chemotherapy regimens have achieved high cure rates
in both adults and children, but treatment-associated tox-
icities are problematic. This issue is of particular concern
for elderly and HIV-infected patients who show inferior
responses and reduced tolerance of treatment-associated
toxicities [40]. Treatment success has improved with the
use of anti-CD20 monoclonal antibody, rituximab [41].
However, toxicities remain problematic, and the use of an
immunosuppressive in HIV-infected patients is a subject
of ongoing debate [42, 43]. While current treatments for
BL have shown overall success, there is obvious room for
improvement in the treatment of elderly and HIV-infected
patients. Our future studies will continue to evaluate the role
ofbryostatin-1inrestoringclassII-mediatedAgpresentation
in BL and determine the immunostimulatory role of the
peptidylprolyl-like protein. A better understanding of these
factors may lead to development of novel immunotherapies
which could augment, lessen, or eliminate the need for toxic
chemotherapies.
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